Eli Lilly's weight-loss pill Foundayo wins EU regulatory backing

On October 16, 2026, the European Medicines Agency recommended approval of Eli Lilly's once-daily weight-loss pill Foundayo for obesity and type 2 diabetes, paving the way for European Commission clearance. Foundayo, containing orforglipron, reduced body weight by up to 11% in trials of over 4,740 adults. Eli Lilly and rival Novo Nordisk are competing for dominance in an oral obesity drug market projected to top $100 billion by 2030, with Lilly highlighting Foundayo's flexible dosing without food or water restrictions.

Foundayo mechanism and clinical trial results

• ▪The European Medicines Agency based its recommendation of Eli Lilly's Foundayo on two clinical studies involving more than 4,740 obese or overweight adults
• ▪Patients treated with Eli Lilly's weight-loss pill Foundayo lost up to 11% of their body weight in clinical trials
• ▪Eli Lilly's Foundayo contains orforglipron, a small-molecule GLP-1 receptor agonist that helps reduce appetite and food intake

Foundayo's dosing advantages over Wegovy

• ▪Eli Lilly has promoted the absence of food and water restrictions for Foundayo as a key competitive advantage over alternative oral weight-loss drugs
• ▪Unlike Novo Nordisk's Wegovy pill, Eli Lilly's Foundayo can be taken at any time of day without food or water restrictions

Global rollouts and sales performance

• ▪Eli Lilly introduced its weight-loss pill Foundayo to the United Kingdom market in August 2026
• ▪Eli Lilly launched Foundayo in the United States in April 2026, generating $98 million in second-quarter 2026 sales
• ▪Eli Lilly's Foundayo has experienced slower initial uptake in the United States market compared to Novo Nordisk's Wegovy pill
• ▪Eli Lilly has sought regulatory approval for its weight-loss pill Foundayo in more than 40 countries worldwide

Oral obesity market competition and projection

• ▪Novo Nordisk's Wegovy pill is commercially available in the United Kingdom, the United States, and the United Arab Emirates
• ▪Early United States prescription data indicates that oral weight-loss drugs could expand the oral obesity drug market by attracting patients hesitant to use injectable treatments
• ▪Novo Nordisk's Wegovy pill generated 3.22 billion Danish crowns ($484.50 million) in second-quarter 2026 sales after winning European Union approval in July 2026
• ▪Eli Lilly's Foundayo is the second oral obesity drug to receive European Medicines Agency backing, following Novo Nordisk's Wegovy pill